Cargando…
Rasagiline Pharmacokinetics in CYP1A2 Variant Healthy Smokers & Non-smokers in Different Doses
OBJECTIVES: Rasagiline, a drug for Parkinson’s disease is metabolized by CYP1A2 enzyme. The objective of the study was to investigate the influence of cytochrome P450 1A2 variants and smoking status of healthy individuals on the pharmacokinetics of rasagiline. METHODS: A comparative, open label, int...
Autores principales: | Bilal, Rabiea, Ahmad, Naseem Saud, Zaffar, Sehrish, Mazhar, Muhammad Usama, Siddiqui, Waqar Ahmed, Tariq, Saba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Professional Medical Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002453/ https://www.ncbi.nlm.nih.gov/pubmed/35480532 http://dx.doi.org/10.12669/pjms.38.3.4940 |
Ejemplares similares
-
Are healthy smokers really healthy?
por: Zhou, Zijing, et al.
Publicado: (2016) -
Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis
por: Marchand, Mathilde, et al.
Publicado: (2017) -
Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers
por: Chen, Qiuying, et al.
Publicado: (2015) -
The Spasmolytic Effect of Astragalus Sarcocolla on the Intestinal Smooth Muscles of Rabbit In Vitro: Potassium Channel Opening
por: Siddiqui, Waqar Ahmed, et al.
Publicado: (2020) -
Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
por: Rasmussen, Scott, et al.
Publicado: (2018)